Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOBOE: Adjuvant Therapy in Premenopausal Breast Cancer
NCT00412022Phase 3Unknown
- Sponsor
- National Cancer Institute
- Start
- Mar 2004
- Primary completion
- Nov 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of letrozole and zoledronic acid in breast cancer (3 arms), sponsored by National Cancer Institute. Primary endpoints: Disease Free Survival at 10 years and Bone Mineral Density at 12 months. Status: unknown.
02
Drugs
letrozolezoledronic acid
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00412022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00412022.